Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PEOPLE - Changes at Arrow International:

This article was originally published in Clinica

Executive Summary

Reading, Pennsylvania-based Arrow International, a manufacturer of catheters for cardiac care, has made several management changes. Frederick Hirt has been promoted to senior vice-president of finance and CFO. He will also continue his role as a member of the management executive committee. Fellow member Carl Staples, head of human resources, has been appointed senior vice-president of HR. Philip Croxford has been promoted to group vice-president of critical care and cardiac assist and will become a member of the committee. James Hatlan has been promoted to senior vice-president of manufacturing and also becomes a member of the committee. The firm also announced the retirement of Philip Fleck, Arrow's president and COO, effective December 31 2004.

You may also be interested in...



Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel